Clinical Trial Search

Primary: Complete Clinical Response (CCR) of Lesion at Days 50, 100 and 180 (+7 Days) — 47; 30; 3; 12 Participants

Primary: The Primary Safety Endpoint - Frequency of Complications of Therapy — 414 participants

Primary: Number of Participants That Discontinued Due to Adverse Experience, by Type of Adverse Experience — 12; 10; 3; 1 Participants

Primary: Complete Clinical Response — 85; 103; 86 participants

Primary: True Positive — 0 samples

Primary: Safety: Overview of Adverse Events — 16; 7; 0; 0 Participants

Primary: Number of Participants With Clinical Cure of Lesions — 3 Participants

Primary: Date of Clinical Cure — 2; 2; 15; 10 participants

Primary: Final Clinical Cure Rate — 101; 102; 73 participants — p=0.0001

Primary: Equivalence of Efficacy Assessed by the Number of Participants With Clinical Cure — 22; 18; 5; 9 Participants

Primary: Number of Participants Who Obtained Final Clinical Cure of Index Lesion — 9; 13 Participants

Primary: Percent of Participants With Final Clinical Cure — 78.6; 77.8 percent of participants

Primary: Probability of Relapse-free Survival — 79; 71 percentage probability

Primary: Final Clinical Cure for Index Lesions — 11; 9 participants

Primary: Positive Result Comparison: CL Detect Rapid Test With Microscopy and Culture Results — 147; 144; 96 Participants

Primary: Clinical Response — 32; 25; 28 Participants

Primary: Sensitizing Effects of LtSTA in Leishmania Naive Adults — 8; 22; 9 participants

Primary: Dermatology Life Quality Index (DLQI) Domain Scores — 3; 0; 1; 0 units on a scale

Primary: Percentage of Participants With a Successful Response as Measured by Qualitative Polymerase Chain Reaction — 15.6; 10.0; 82.1; 86.7 Percentage of participants

Primary: Malaria Diagnosis Using RealAmp and Microscopy. — 42; 153; 0; 1 Participants

Primary: Global PCR (Conventional PCR and Real-time Quantitative PCR) Immediately After the End of Treatment. — 16; 20 Participants

Primary: Cross-reactive Antigenemia — 12 Participants

Primary: Clearance of Microfilaremia (IA vs. MoxA) — 8; 18; 24; 27 Participants

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of L9LS Product Administration — 2; 3; 3; 4 Participants

Primary: Microfilarial Counts at 1 Year — 0; 0; 0 MF/ML — p=<0.2

Primary: Infection Rate — 5; 6; 3; 0 Participants